Katalin Karikó is a Hungarian-American biochemist whose four decades of research on messenger RNA helped turn a fragile, inflammatory laboratory molecule into a practical therapeutic platform. Working with immunologist Drew Weissman at the University of Pennsylvania, she discovered that modifying particular nucleoside bases in laboratory-produced mRNA could prevent the excessive innate immune response that had limited its medical use while improving its ability to produce proteins. The work became a foundational component of the Pfizer-BioNTech and Moderna COVID-19 vaccines and established modified mRNA as a platform now being investigated across infectious disease, cancer, protein replacement, immunotherapy and other areas of medicine. In 2023, Karikó and Weissman received the Nobel Prize in Physiology or Medicine for the discoveries. Nobel Prize
Category: Pioneer
Field: Biochemistry · Molecular Biology · mRNA Therapeutics · Biotechnology · Medicine
The biochemist who spent decades developing messenger RNA when much of science considered it impractical, then helped establish the molecular technology behind the first widely deployed mRNA medicines.
At a Glance
Karikó’s career is an unusually clear case study in the distance between a scientific idea and a usable technology. The basic proposition — that messenger RNA could temporarily instruct human cells to manufacture a therapeutic protein — existed decades before COVID-19. The problem was that laboratory-produced mRNA was unstable, difficult to deliver and capable of triggering an inflammatory immune response that made it poorly suited for medicine. Karikó spent much of her career working on those underlying constraints. Her collaboration with Weissman identified a critical molecular solution in 2005; subsequent research improved protein production, purification and the practical performance of modified mRNA. Other scientific advances in lipid-nanoparticle delivery, antigen design, manufacturing and clinical development eventually combined with that work to produce the COVID-19 vaccines. Nobel Prize
| Category | Details |
|---|---|
| Born | January 17, 1955 · Szolnok, Hungary |
| Raised | Kisújszállás, Hungary |
| Country | Hungary · United States |
| Field | Biochemistry, molecular biology, RNA therapeutics and biotechnology |
| Known For | Pioneering nucleoside-modified mRNA technology with Drew Weissman |
| Education | B.S. Biology, József Attila University, 1978; Ph.D. Biochemistry, University of Szeged/József Attila University, 1982 |
| Major Roles / Organizations | Biological Research Centre, Szeged; Temple University; University of Pennsylvania; RNARx; BioNTech; University of Szeged |
| Current Roles | Professor, University of Szeged; Adjunct Professor of Neurosurgery, University of Pennsylvania |
| Major Milestone | Co-recipient of the 2023 Nobel Prize in Physiology or Medicine |
| First / Record | First Hungarian woman to receive a Nobel Prize |
| GDT Category | Pioneer |
The Nobel Assembly awarded Karikó and Weissman the 2023 prize “for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.” Nobel Prize
Why She’s a Girls Do That Champion
Karikó’s career is frequently reduced to a story about perseverance.
That is true, but incomplete.
The more important lesson is technical judgment.
For decades, she continued working on messenger RNA because she believed the molecule had properties that made it unusually useful for medicine.
The underlying idea is elegant.
Human cells already contain machinery for manufacturing proteins.
DNA stores genetic information.
Messenger RNA carries temporary instructions from DNA to cellular machinery called ribosomes, which read those instructions and assemble proteins.
A therapeutic mRNA therefore does not necessarily need to supply the finished medicine.
It can supply the instructions for making it.
The cell becomes the production system.
That architecture potentially changes how medicines can be designed. Once scientists know the genetic sequence encoding a useful protein, the informational component of the therapy can be redesigned without rebuilding an entirely different manufacturing platform from the beginning.
The idea was powerful.
The molecule was difficult.
Karikó’s significance lies in spending decades on the difficult part.
Her work also illustrates something important about scientific systems.
Transformative technologies rarely emerge from a single breakthrough.
The COVID-19 mRNA vaccines required contributions from numerous research programmes:
basic RNA biology,
nucleoside modification,
mRNA purification,
lipid nanoparticles,
structural biology,
coronavirus research,
antigen stabilization,
genomic sequencing,
industrial manufacturing,
clinical trials,
regulation,
and enormous public and private investment.
Karikó and Weissman solved one particularly important bottleneck.
The Nobel Committee concluded that their discovery was critical for making the mRNA platform suitable for clinical use. Nobel Prize
For Girls Do That, her career demonstrates a different form of pioneering.
Sometimes the breakthrough is not inventing an entirely new system.
It is identifying the constraint preventing an existing idea from working — and staying with the problem long enough to remove it.
Her Story
Kisújszállás
Katalin Karikó was born in Szolnok, Hungary, in 1955 and grew up in Kisújszállás, a small town of approximately 10,000 people.
Her father worked as a butcher.
Her family lived modestly, and Karikó grew up closely observing animals, plants and ordinary biological processes around her. She has recalled climbing trees to inspect bird nests and watching a neighbour’s cow give birth.
She had not personally met a scientist.
She decided she wanted to become one anyway.
Karikó credits teachers with converting that curiosity into an imaginable profession. In particular, her secondary-school biology teacher, Albert Tóth, repeatedly told her that she could become a researcher.
Years later, she remembered the effect plainly: she eventually believed him. Lasker Foundation
Szeged
At 16, Karikó began attending university preparatory programmes designed for students from working-class families.
In 1973, she entered the biology programme at József Attila University in Szeged, now the University of Szeged.
She graduated in biology in 1978 and continued into doctoral research in biochemistry at the nearby Biological Research Centre of the Hungarian Academy of Sciences.
Her doctoral work concerned antiviral mechanisms involving short RNA-related molecules called 2′-5′-linked oligoadenylates.
She received her Ph.D. in 1982. SZTE Mediateka
RNA was already becoming the centre of her scientific life.
What mRNA Does
Cells need proteins to perform most biological functions.
DNA contains the long-term genetic instructions.
But the DNA generally remains protected inside the cell nucleus.
When a cell needs to make a protein, it creates a temporary molecular copy of the relevant genetic instructions.
That copy is messenger RNA, or mRNA.
The mRNA moves to cellular machinery called ribosomes.
The ribosome reads the sequence.
A protein is produced.
Then the mRNA is degraded.
That temporary character is part of what made mRNA interesting as a therapeutic tool.
Instead of permanently altering a cell’s DNA, researchers could potentially provide a short-lived set of instructions.
The cell could manufacture the desired protein.
The instructions would subsequently disappear.
The theoretical applications were broad.
A therapeutic mRNA could potentially instruct cells to produce:
an antigen for a vaccine,
a missing protein,
an antibody,
a cancer-associated target,
or another biologically useful molecule.
The question was whether synthetic mRNA could survive long enough, reach the appropriate cells and produce enough protein without creating harmful inflammatory responses.
For years, the answer was largely:
not reliably.
Coming to America
In 1985, Karikó and her husband Béla Francia left Hungary for the United States with their young daughter.
Hungarian currency restrictions limited how much money families could legally take abroad. After selling their car, the family converted their savings and concealed approximately $1,200 inside their daughter’s teddy bear for the move.
Karikó arrived in Philadelphia for a postdoctoral research position at Temple University. PenguinRandomhouse.com
She later worked at the Uniformed Services University of the Health Sciences in Bethesda, Maryland, where she deepened her work in molecular biology and interferon biology.
Then, in 1989, she joined the University of Pennsylvania.
That would become the central institutional setting for her work on therapeutic mRNA.
The mRNA Bet
At Penn, Karikó increasingly focused on one question:
Could synthetic messenger RNA be used to make therapeutic proteins inside the body?
The proposition was technically difficult.
mRNA is transient.
It can be degraded quickly.
Getting it into cells is difficult.
And the immune system is designed to detect molecular patterns associated with pathogens.
Foreign RNA can look suspicious.
From the immune system’s perspective, that is useful.
From the perspective of someone trying to administer RNA as medicine, it is a problem.
Karikó nevertheless began designing experiments around the therapeutic potential of in vitro-transcribed mRNA — mRNA produced outside a cell in the laboratory.
Her early work demonstrated that laboratory-produced mRNA introduced into mammalian cells could direct those cells to manufacture functional proteins. SZTE Mediateka
The basic mechanism worked.
The clinical platform did not yet.
A Scientific Funding Problem
During the 1990s, enthusiasm for mRNA was limited.
Other gene-therapy technologies appeared more promising.
Synthetic mRNA was considered too unstable and inflammatory.
Karikó repeatedly applied for research funding.
The grants were rejected.
In 1995, after failing to progress through the conventional academic promotion system, she accepted a demotion at Penn rather than leave the institution and abandon the research direction. SZTE Mediateka
This period is often narrated as evidence that everyone else was wrong and Karikó alone was right.
The scientific reality is more complicated.
mRNA genuinely had major technical problems.
The scepticism did not arise from nothing.
What distinguished Karikó was her conclusion about those problems.
She did not interpret them as proof that mRNA could never become a medicine.
She treated them as engineering and biological constraints that might be solved.
Staying at the Bench
Karikó’s response to the demotion was unusually pragmatic.
She still had access to a laboratory bench.
She could still conduct experiments.
She stayed.
Years later she described the logic in a Nobel Prize conversation: she had been demoted, but the bench was still there, and she could still work. Nobel Prize
That distinction is important.
Academic rank was one system of measurement.
Experimental progress was another.
Karikó increasingly prioritized the second.
The Copy Machine
In the late 1990s, Karikó met immunologist Drew Weissman at a University of Pennsylvania photocopier.
The setting has become part of scientific folklore, but the partnership worked because the two researchers brought different questions to the same molecule.
Karikó understood RNA.
Weissman was studying immunology and vaccines, including how immune cells recognize pathogens.
He wanted to use mRNA to instruct dendritic cells, important cells in the immune system, to produce proteins that could stimulate an immune response.
They began collaborating. Penn Medicine
Very quickly, they encountered the problem that had haunted mRNA therapeutics.
The RNA was provoking inflammation.
The failure became the research question.
Why Was the Immune System Rejecting the RNA?
The immune system contains receptors that recognize molecular patterns commonly associated with infection.
Among them are Toll-like receptors, including TLR3, TLR7 and TLR8.
When immune cells encountered laboratory-produced RNA, these receptors could interpret it as foreign material and trigger inflammatory signalling.
Karikó and Weissman compared different forms of RNA.
They noticed something important.
RNA naturally produced by mammalian cells contains numerous chemical modifications to its constituent nucleosides.
Laboratory-produced mRNA generally did not.
That suggested a possibility:
perhaps the immune system was responding not simply because the molecule was RNA, but because the RNA lacked modifications normally present in biological RNA.
They began testing modified nucleosides.
The 2005 Discovery
In 2005, Karikó and Weissman published the paper that would eventually earn them the Nobel Prize.
They demonstrated that incorporating certain naturally occurring modified nucleosides into laboratory-produced mRNA could dramatically reduce the inflammatory response generated by immune cells.
One of the most important was pseudouridine.
The modification allowed the mRNA to avoid activation of important innate immune receptors.
The Nobel Committee later concluded that the discovery fundamentally changed understanding of how cells interact with different forms of mRNA. Nobel Prize
At a molecular level, the change was small.
At a technological level, it was substantial.
The researchers had demonstrated that mRNA’s immunogenicity was not necessarily an unavoidable property of the platform.
It could be engineered.
A Platform Becomes More Practical
Reducing inflammation was only part of the problem.
A useful therapeutic also needs to produce enough protein.
Karikó, Weissman and collaborators subsequently demonstrated that pseudouridine-containing mRNA could produce substantially more protein while provoking less immune activation than conventional laboratory-produced mRNA.
Further research across the field identified additional modifications, including N1-methylpseudouridine, which improved the platform further and became the uridine modification used in the Pfizer-BioNTech and Moderna COVID-19 vaccines. Nobel Prize
Karikó also worked on methods for improving the purity of mRNA preparations, another important factor in limiting inflammatory responses and improving protein production. SZTE Mediateka
The technology was becoming progressively more usable.
Why This Was Not Yet a Vaccine
The 2005 discovery did not produce a finished COVID-19 vaccine.
COVID-19 did not yet exist.
Nor did nucleoside modification solve every problem involved in mRNA medicine.
A therapeutic platform still needed:
effective delivery,
protection of the fragile mRNA molecule,
appropriate dosing,
manufacturing processes,
a biological target,
clinical testing,
regulatory approval,
and the ability to produce billions of doses.
One especially important complementary development was lipid nanoparticle technology, which packages mRNA inside microscopic lipid structures that protect it and help deliver it into cells.
The Nobel Committee explicitly identified efficient delivery systems, coronavirus antigen design and massive industrial investment as additional components that eventually combined with the Karikó-Weissman discovery. Nobel Prize
That distinction matters because major technologies are almost always systems assembled from multiple breakthroughs.
Karikó and Weissman solved a foundational biological problem.
Other researchers and organizations solved others.
From Research Paper to Intellectual Property
Penn patented aspects of the modified-mRNA technology developed by Karikó and Weissman.
Those patents became part of a licensing chain that eventually placed the technology inside commercial biotechnology platforms.
The intellectual-property structure is important because scientific publication alone does not convert a laboratory discovery into a manufactured medicine.
Technology transfer connects research to organizations capable of financing development, running clinical trials, building manufacturing capacity and navigating regulation.
University of Pennsylvania modified-mRNA patents were licensed through mRNA RiboTherapeutics and Cellscript. Moderna later obtained sublicenses covering parts of that technology. SEC
The Pfizer-BioNTech and Moderna COVID-19 vaccines both ultimately incorporated licensed Penn modified-mRNA technology. Penn Medicine
RNARx
Karikó and Weissman also attempted to move the technology toward commercialization themselves.
They co-founded RNARx, a company focused on developing nucleoside-modified mRNA therapeutics.
Karikó served as chief executive from 2006 to 2013. SZTE Mediateka
The company did not become the commercial platform through which modified mRNA reached global scale.
That role would be played by other companies.
But RNARx is an important part of the career chronology because it shows that Karikó understood the translational problem.
A laboratory discovery is not automatically a medicine.
Between discovery and treatment sits an entire system:
intellectual property,
capital,
clinical development,
regulation,
manufacturing,
distribution,
and commercial adoption.
BioNTech
In 2013, Karikó met Uğur Şahin and other researchers from the German biotechnology company BioNTech.
Unlike many of the environments she had encountered earlier in her career, the company was already deeply committed to messenger RNA.
Karikó later recalled that she did not have to convince the team that RNA was useful.
They already believed in the platform.
Şahin invited her to join the company.
She accepted. BioNTech
Karikó left Penn as a full-time employee and moved to BioNTech in Mainz, Germany.
She initially became a vice president and was later promoted to Senior Vice President.
At BioNTech, she worked on advancing mRNA-based therapeutics and protein replacement, placing her inside an organization attempting to translate RNA science into medicines at industrial scale. SZTE Mediateka
A New Drug Class
In 2014, Karikó, Şahin and BioNTech co-founder Özlem Türeci published a major review in Nature Reviews Drug Discovery describing mRNA therapeutics as a potential new class of drugs.
The paper examined the platform’s applications, delivery challenges, manufacturing considerations and therapeutic possibilities.
The framing is important.
mRNA was no longer being treated merely as a candidate for one vaccine.
It was being developed as a platform technology.
A platform is valuable because its core architecture can be reused.
Change the sequence carried by the mRNA, and the biological output changes.
The manufacturing logic can remain substantially similar.
That makes mRNA potentially applicable across many different diseases. BioNTech
Then Came SARS-CoV-2
At the end of 2019, a novel coronavirus began spreading.
Chinese researchers rapidly published the genetic sequence of SARS-CoV-2 in January 2020.
That sequence gave vaccine researchers the information needed to begin designing candidates.
mRNA platforms had a particular advantage in this environment.
Researchers did not need to grow large quantities of the virus before beginning vaccine design.
They could manufacture an mRNA sequence containing instructions for producing a viral antigen.
The body would manufacture the antigen.
The immune system would learn to recognize it.
The platform that had spent decades being considered impractical suddenly offered exactly the type of development speed a pandemic required.
Project Lightspeed
BioNTech initiated Project Lightspeed in early 2020 to develop an mRNA vaccine against COVID-19.
The company evaluated more than 20 vaccine candidates.
The programme ultimately advanced BNT162b2, built around nucleoside-modified mRNA.
BioNTech partnered with Pfizer for large-scale clinical development, manufacturing and distribution. BioNTech
Moderna independently developed another nucleoside-modified mRNA vaccine.
Both vaccines used the molecular principle Karikó and Weissman had helped establish years earlier.
December 2020
By December 2020, regulators began authorizing the first mRNA COVID-19 vaccines.
The speed appeared extraordinary.
But the underlying technology was not new.
Karikó had been working on RNA since the late 1970s.
Her therapeutic mRNA work at Penn began around 1990.
The critical nucleoside-modification discovery was published in 2005.
Commercial and academic groups had spent the following 15 years improving mRNA chemistry, delivery, manufacturing and vaccine applications.
The pandemic compressed the final development programme.
It did not create the science overnight.
On December 18, 2020, Karikó and Weissman received their first Pfizer-BioNTech COVID-19 vaccine doses together at Penn.
The researchers were being injected with a medicine built partly on the technology they had developed at the same institution more than fifteen years earlier. Penn Medicine
The Platform Effect
The significance of the COVID-19 vaccines extended beyond the pandemic.
They validated modified mRNA in humans at unprecedented scale.
That changed the economics of an entire research field.
Before 2020, developers of mRNA medicines still faced a basic question:
Can this platform work at global clinical scale?
After the COVID-19 vaccination programmes, that question had a very different answer.
Research intensified across:
influenza,
HIV,
herpes,
other coronaviruses,
bacterial infections,
cancer vaccines,
protein replacement,
gene-editing delivery,
autoimmune disease,
and regenerative medicine.
Penn researchers, BioNTech, Moderna and numerous other biotechnology companies continue developing applications based on the broader mRNA platform. Penn Medicine
The downstream field is much larger than any one scientist.
That is precisely what defines a platform breakthrough.
Recognition Arrives
For most of Karikó’s scientific career, recognition was limited.
Then it arrived very quickly.
In 2021 alone, Karikó and Weissman received or shared major honours including the Lasker-DeBakey Clinical Medical Research Award, Princess of Asturias Award for Technical and Scientific Research, Albany Medical Center Prize, and several other international science prizes. Lasker Foundation
The Breakthrough Prize in Life Sciences followed for engineering modified RNA technology that enabled rapid development of effective COVID-19 vaccines. Breakthrough Prize
In 2022, Karikó and Weissman received the Japan Prize for pioneering research contributing to the development of mRNA vaccines. Japan Prize
Then came Stockholm.
The Nobel Prize
On October 2, 2023, the Nobel Assembly at Karolinska Institutet announced that Katalin Karikó and Drew Weissman would share the Nobel Prize in Physiology or Medicine.
The citation focused specifically on their discoveries concerning nucleoside-base modifications and their role in enabling effective mRNA vaccines against COVID-19. Nobel Prize
The Nobel Committee’s scientific explanation was careful about attribution.
Karikó and Weissman’s work did not independently produce the vaccines.
Their discovery combined with:
mRNA-delivery technology,
stabilization of the SARS-CoV-2 spike antigen,
other advances in vaccine science,
and extraordinary investments from governments and industry.
Together, those systems produced the vaccines. Nobel Prize
That framing gives a more useful account of innovation than the mythology of a lone inventor.
Modern biomedical breakthroughs are networks.
Karikó’s contribution became indispensable because other contributions could connect to it.
The First Hungarian Woman Nobel Laureate
Karikó’s Nobel Prize also made her the first Hungarian woman to receive a Nobel Prize.
For the University of Szeged, the recognition had particular historical resonance.
The university is also associated with Albert Szent-Györgyi, who received the Nobel Prize in Physiology or Medicine in 1937 for discoveries connected with vitamin C.
After Karikó’s Nobel Prize, the university assigned her the former study used by Szent-Györgyi. SZTE Klebelsberg Library
But Karikó chose to turn another part of the prize into something less symbolic.
Giving the Nobel Money Back to Science
In April 2024, Karikó returned to the University of Szeged and announced that she was donating more than $500,000 from her Nobel Prize money to her alma mater.
She also donated an authenticated replica of her Nobel medal for public display. University of Szeged
The money became the basis of the JATE Award, named after the university’s former name, József Attila University.
The programme is designed to recognize outstanding achievement by both a university researcher-educator and a student.
Each annual award carries a $10,000 prize. University of Szeged
The structure is particularly consistent with Karikó’s own career.
One award recognizes an established researcher.
The other recognizes someone still entering the system.
Capital generated by recognition of one scientific career is therefore recycled into the next generation of scientific work.
The JATE Award as a Research Pipeline
The donation can be understood as more than philanthropy.
It creates a small research-incentive system.
Karikó herself has repeatedly said that awards were not what motivated her.
But she recognizes that awards can draw attention to scientific work and signal to younger researchers that their effort is visible.
She explained that one of the most influential moments in her own education was not financial.
It was a teacher telling her:
“Kati, you can become a researcher.”
She heard it repeatedly.
Eventually, she believed it. University of Szeged
The JATE Award institutionalizes a similar signalling function.
Someone identifies promising work.
Someone tells the researcher or student:
this matters.
Keep going.
Returning the Archive
Karikó has also transferred important parts of her personal and scientific archive to the University of Szeged.
The university’s Klebelsberg Library maintains a growing Katalin Karikó Collection containing photographs, documents, academic materials and objects associated with her life and scientific development.
The university also operates a permanent exhibition tracing her development from a school student interested in biology to a Nobel laureate. SZTE Mediateka
The archive provides something different from an award.
It preserves process.
Not simply the Nobel medal.
The notebooks, certificates, documents and materials that preceded it.
For young scientists, that distinction is useful.
Scientific careers are made from the work before the headline.
Breaking Through
In October 2023, Karikó published her memoir:
Breaking Through: My Life in Science
The book documents her childhood in Hungary, immigration to the United States, decades of laboratory work, professional setbacks, research partnerships and the eventual emergence of mRNA as a major therapeutic platform. PenguinRandomhouse.com
Its value is partly that Karikó does not narrate her career as a sequence inevitably leading toward the Nobel Prize.
For most of the period described, there was no reason to assume a Nobel Prize was coming.
There was simply another experiment.
Another failed grant.
Another problem with RNA.
Another possible modification.
Another dataset.
Another paper.
That is a more accurate representation of research.
Breakthroughs are obvious retrospectively.
While they are being built, they frequently look like unfinished work.
The Science After the Prize
Karikó left her full-time BioNTech position in 2022 and returned to Pennsylvania, while maintaining a connection to the company as an external consultant.
She continues to hold academic roles at both the University of Szeged and the University of Pennsylvania. BioNTech
Her scientific legacy is now being extended by a much larger research ecosystem.
At Penn, the Institute for RNA Innovation and collaborating laboratories are developing mRNA approaches for:
universal influenza vaccines,
pan-coronavirus vaccines,
HIV,
herpes simplex virus,
Lyme disease,
norovirus,
C. difficile,
gene therapy,
cardiovascular disease,
and other conditions. Penn Medicine
BioNTech continues developing mRNA-based cancer immunotherapies and other treatment platforms. BioNTech
The technology has therefore moved into a stage Karikó spent decades trying to reach.
Researchers no longer need to begin every conversation by arguing that messenger RNA might one day become useful medicine.
They can begin with:
What should we use it to build next?
The Infrastructure Behind a Breakthrough
Karikó’s career is useful because it reveals the different systems required to turn knowledge into medicine.
| Layer | Problem | Contribution |
|---|---|---|
| Basic RNA biology | Could laboratory-produced mRNA reliably make functional proteins? | Karikó spent decades optimizing in-vitro-transcribed mRNA for therapeutic use |
| Innate immunity | Synthetic mRNA triggered inflammatory immune responses | Karikó and Weissman showed that nucleoside modification could suppress this recognition |
| Protein production | Therapeutic mRNA needed sufficient biological output | Modified mRNA improved protein production as well as tolerability |
| Purification | RNA preparations contained inflammatory by-products | Karikó and collaborators developed purification approaches that improved performance |
| Intellectual property | Laboratory discoveries needed translational pathways | Penn patented modified-mRNA technologies and licensed them into biotechnology |
| Commercial development | Research needed industrial development capability | BioNTech, Moderna and other firms developed mRNA platforms at commercial scale |
| Delivery | mRNA needs protection and transport into cells | Lipid-nanoparticle technologies developed by other researchers became a critical complementary layer |
| Antigen design | A COVID vaccine needed the correct viral target | Coronavirus and structural-biology research supplied stabilized spike-antigen designs |
| Manufacturing | Billions of doses required global industrial capacity | Pharmaceutical manufacturing networks scaled production |
| Research pipeline | Future scientists need resources and institutional recognition | Karikó used Nobel funds to establish the JATE Award at the University of Szeged |
The table makes clear why the phrase “Karikó invented the COVID vaccine” would be inaccurate.
It also makes clear why her contribution was foundational.
Remove the modified-mRNA layer, and the system that produced the first COVID-19 mRNA vaccines changes fundamentally.
What Katalin Karikó Changed
The systems question is straightforward:
What became possible after the Karikó-Weissman discovery that had not been practical before it?
Before their work, synthetic mRNA’s tendency to activate innate immunity represented a major obstacle to therapeutic use.
Their research identified why part of that reaction occurred and demonstrated a way to reduce it.
Subsequent research improved translation and purification.
That created a more practical mRNA platform.
Biotechnology companies could develop the platform.
Delivery scientists could package it.
Vaccine researchers could insert new antigen sequences.
Manufacturers could scale it.
Regulators could evaluate it.
Patients could receive it.
The scientific contribution therefore sits at a critical junction between molecular biology and platform medicine.
That is why the work became consequential at global scale.
A Career Measured Differently
For much of Karikó’s professional life, conventional institutional indicators suggested limited success.
Grant funding was difficult.
Promotion stalled.
She accepted demotion.
Her field attracted limited enthusiasm.
Her major paper did not initially transform the scientific establishment.
Those indicators were real.
But they were measuring something different from whether the underlying biology was correct.
The distinction matters beyond science.
Institutions need evaluation systems.
But evaluation systems are proxies.
Grant panels predict which research is worth funding.
Promotion committees predict which researchers warrant investment.
Citation systems measure influence.
Venture investors estimate commercial possibility.
None of them directly measure future truth.
Science ultimately does.
An experiment works or it does not.
A mechanism survives replication or it does not.
A technology eventually produces useful outcomes or it does not.
Karikó spent decades being weakly rewarded by one system while accumulating evidence in another.
Eventually, the second system changed the first.
Milestones
| Year | Milestone |
|---|---|
| 1955 | Born January 17 in Szolnok, Hungary; raised in Kisújszállás |
| 1973 | Enters biology studies at József Attila University in Szeged |
| 1978 | Graduates in biology |
| 1982 | Earns Ph.D. in biochemistry; conducts research at the Biological Research Centre in Szeged |
| 1985 | Moves with her family to the United States and begins postdoctoral research at Temple University |
| 1988 | Conducts research at the Uniformed Services University of the Health Sciences in Bethesda |
| 1989 | Joins the University of Pennsylvania |
| Early 1990s | Develops therapeutic applications of in-vitro-transcribed messenger RNA |
| 1995 | Accepts demotion at Penn after repeated difficulty obtaining research funding |
| Late 1990s | Begins collaboration with immunologist Drew Weissman |
| 2005 | Karikó and Weissman publish their landmark discovery showing that nucleoside modifications can suppress inflammatory recognition of mRNA |
| 2006 | Co-founds RNARx with Weissman to pursue modified-mRNA therapeutics |
| 2008 | Follow-up research demonstrates improved protein production and reduced immunogenicity from pseudouridine-containing mRNA |
| 2013 | Joins BioNTech in Mainz, Germany, as a vice president |
| 2014 | Co-authors major review describing mRNA therapeutics as a new drug class |
| 2019 | Promoted to Senior Vice President at BioNTech |
| 2020 | Modified-mRNA technology becomes a foundational component of Pfizer-BioNTech and Moderna COVID-19 vaccines |
| December 2020 | Receives the Pfizer-BioNTech vaccine at Penn alongside Drew Weissman |
| 2021 | Receives Lasker-DeBakey Clinical Medical Research Award and Princess of Asturias Award, among numerous honours |
| 2022 | Receives Japan Prize and Breakthrough Prize recognition for modified mRNA technology; leaves full-time BioNTech role |
| 2023 | Publishes Breaking Through: My Life in Science |
| October 2023 | Awarded Nobel Prize in Physiology or Medicine with Drew Weissman |
| 2024 | Donates more than $500,000 in Nobel Prize money to the University of Szeged |
| 2024 | Establishes JATE Award supporting outstanding researchers, educators and students |
| 2024 | Donates authenticated Nobel medal replica for permanent exhibition at the University of Szeged |
| 2024–present | Continues academic work through the University of Szeged and University of Pennsylvania |
| 2026 | Continues scientific education and public engagement while modified-mRNA research expands across infectious disease, cancer and other therapeutic areas |
In Her Own Words
“I feel humbled, and happy.”
— Katalin Karikó, after receiving the COVID-19 vaccine built on the mRNA platform she helped develop, Penn Medicine
“The bench is here.”
— Katalin Karikó, recalling why she continued working after being demoted at Penn, Nobel Prize Conversations
“The responsibility of a researcher as a woman is no different: to do what one’s job is, to help others with integrity.”
— Katalin Karikó, University of Szeged
Read · Watch · Listen
Read
Breaking Through: My Life in Science — Katalin Karikó
Karikó’s account of growing up in Hungary, immigrating to the United States, working through decades of professional instability and developing messenger RNA as a therapeutic platform.
The Nobel Prize in Physiology or Medicine 2023 — Advanced Scientific Information
The clearest technical account of exactly what Karikó and Weissman discovered, how nucleoside modification changes innate immune recognition, and how their findings fit alongside delivery technology and other developments that produced COVID-19 mRNA vaccines.
Modified mRNA Vaccines — Lasker Foundation
A detailed scientific and historical account of the work for which Karikó and Weissman received the 2021 Lasker-DeBakey Clinical Medical Research Award.
Katalin Karikó — University of Szeged
An extensive institutional archive covering her education, research in Hungary and the United States, scientific publications, awards and the development of modified mRNA.
Watch
Developing mRNA for Therapy — Nobel Prize Lecture
Karikó’s Nobel lecture traces the scientific development of therapeutic mRNA, including the experiments and molecular modifications behind the work recognized by the Nobel Assembly.
Official Nobel Prize Interview — Katalin Karikó
A conversation recorded during Nobel Week on scientific curiosity, maintaining focus through setbacks, mentorship and advice to researchers.
Listen
Nobel Prize Conversations — Katalin Karikó
A long-form conversation about demotion, rejection, scientific work, family and how Karikó thinks about professional setbacks.
Go Deeper
Katalin Karikó — Nobel Prize
Scientific biography, award documents, interview, lecture and podcast.
Katalin Karikó — University of Pennsylvania
Current academic profile and research background.
University of Pennsylvania profile
Katalin Karikó Collection — University of Szeged
Digital archive of photographs, documents and scientific materials.
BioNTech
The biotechnology company where Karikó served as Vice President and later Senior Vice President while advancing mRNA therapeutics.
JATE Award and Nobel Donation — University of Szeged
Documentation of Karikó’s donation of more than half a million dollars from her Nobel Prize to support future researchers and students.
Sources & Further Reading
APA 7th Edition
BioNTech. (2023, October 2). Statement on Katalin Karikó and Drew Weissman awarded the Nobel Prize in Medicine 2023. BioNTech
Breakthrough Prize. (2021, September 9). Winners of the 2022 Breakthrough Prizes in life sciences, fundamental physics and mathematics announced. Breakthrough Prize
Karikó, K. (2023). Breaking through: My life in science. Crown. Penguin Random House
Lasker Foundation. (2021). Modified mRNA vaccines. Lasker Foundation
Nobel Prize Outreach. (2023). Katalin Karikó — Facts. NobelPrize.org
Nobel Prize Outreach. (2023). The Nobel Prize in Physiology or Medicine 2023: Advanced information. NobelPrize.org
Nobel Prize Outreach. (2023, December 7). Developing mRNA for therapy: Nobel Prize lecture by Katalin Karikó. NobelPrize.org
Penn Medicine. (2020, December 23). Penn mRNA biology pioneers receive COVID-19 vaccine enabled by their foundational research. Penn Medicine
Penn Medicine. (2021, August 23). COVID-19 mRNA vaccine that uses fundamental Penn technology receives FDA approval. Penn Medicine
Penn Medicine. (2023, October 2). Katalin Karikó and Drew Weissman, Penn’s historic mRNA vaccine research team, win 2023 Nobel Prize. Penn Medicine
Princess of Asturias Foundation. (2021). Katalin Karikó, Drew Weissman, Philip Felgner, Uğur Şahin, Özlem Türeci, Derrick Rossi and Sarah Gilbert: 2021 Princess of Asturias Award for Technical & Scientific Research. Princess of Asturias Foundation
The Japan Prize Foundation. (2022). Katalin Karikó. Japan Prize Foundation
University of Pennsylvania. (n.d.). Katalin Karikó, PhD. Perelman School of Medicine. University of Pennsylvania
University of Szeged. (n.d.). Katalin Karikó — Biography. University of Szeged
University of Szeged. (2024, April 23). Homecoming of a Nobel laureate: Katalin Karikó’s two-day visit to the University of Szeged. University of Szeged
Pioneer What Others Have Not Yet Proven
Explore the Girls Do That Pioneer Collection, celebrating women and girls whose work establishes new evidence, opens new fields and expands what the next generation knows can be done.
Every collection helps fund a Girls Do That Club for the next generation.
